Peptides 101: What They Are, Why Everyone’s Talking About Them, and What Changed Recently
If you feel like you’re hearing the word “peptides” everywhere lately, you’re not alone. From weight‑loss injections to “recovery stacks” in wellness clinics, peptides have moved from obscure biochemistry into everyday conversation—often without much explanation.
As a quick guide, this post breaks down what peptides actually are, which ones are truly mainstream (like insulin and GLP‑1s), and what’s going on with popular “regenerative” peptides such as BPC‑157, TB‑500, MOTS‑c, Semax, Epitalon and others.
Nothing here is personal medical advice, but it should give you a clear framework for an informed conversation with your own clinician.
***
## First things first: What is a peptide?
At the simplest level, a peptide is a short chain of amino acids—basically, a mini‑protein.
- Amino acids are the building blocks of proteins.
- When you link a handful of amino acids together, you get a peptide.
- When you link hundreds together, you get a protein.
Your body makes thousands of peptides naturally. Many act as hormones or signaling molecules, carrying messages between organs—for example, telling your pancreas to release insulin, or your brain that you’ve eaten enough.
So when we talk about “peptide therapy,” we’re usually talking about using lab‑made versions or analogs of these natural signaling molecules to nudge specific pathways: metabolism, inflammation, tissue repair, cognition, sleep, and more.
***
## Familiar examples: insulin and GLP‑1s are peptides
A lot of the “mystique” around peptides disappears when you realize some of the most common medications in modern medicine are peptide hormones.
### Insulin
- Insulin is a peptide hormone. It’s made up of two peptide chains (A and B) linked together.
- Your pancreas secretes insulin in response to rising blood glucose, helping move glucose into cells where it can be used for energy.
- Injectable insulin used for diabetes is essentially a manufactured peptide designed to mimic or modify this natural hormone.
If you or someone you love uses insulin, you already have firsthand experience with peptide therapy.
### GLP‑1 medications (Ozempic, Wegovy, Mounjaro, Zepbound, etc.)
GLP‑1 stands for glucagon‑like peptide‑1—another peptide hormone produced in the gut. After you eat, GLP‑1 helps:
- Stimulate insulin release in a glucose‑dependent way
- Slow gastric emptying
- Signal satiety to the brain
The GLP‑1 receptor agonists many people use for type 2 diabetes or obesity (semaglutide, liraglutide, tirzepatide, etc.) are peptide drugs modeled on GLP‑1, engineered to last longer in the body and have stronger, more predictable effects. [en.wikipedia](https://en.wikipedia.org/wiki/Glucagon-like_peptide-1)
So again: GLP‑1s are not some separate “category” from peptides—they are peptides.
***
## The “new wave” of peptides: what people are asking about
Beyond insulin and GLP‑1s, you may be hearing about a set of experimental or “longevity” peptides being discussed in athlete circles, biohacking spaces, and some wellness practices.
These are not FDA‑approved drugs. Most of the human data are small, early‑stage, or extrapolated from animal studies. But they’ve become popular enough that the FDA recently reviewed whether they can be used in compounded medications (custom formulations prepared by compounding pharmacies).
Here are some of the names you’ve probably seen, with plain‑language descriptions:
- BPC‑157
Often nicknamed the “Wolverine peptide.” It’s a fragment of a protein found in gastric juice, studied for potential roles in tendon, ligament, muscle, and gut repair and for modulating inflammation. [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
- KPV
A short fragment (Lys‑Pro‑Val) derived from the hormone alpha‑MSH. It’s being explored for wound healing and inflammatory conditions, particularly in the skin and gut. [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
- TB‑500 (thymosin beta‑4 fragment)
Derived from a naturally occurring protein involved in cell migration and tissue repair. TB‑500 is used in research settings for soft‑tissue recovery and wound healing. [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
- MOTS‑c
A mitochondrial‑derived peptide being studied for metabolic regulation, obesity, insulin sensitivity, and bone health (osteoporosis). [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
- Semax
A synthetic analog of ACTH fragments, studied primarily in Eastern Europe for neurological and cognitive conditions (such as ischemic stroke recovery, migraines, and other neurologic disorders). [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
- Epitalon (Epithalamin analog)
A peptide originally derived from pineal gland research, often marketed for sleep, circadian rhythm support, and “anti‑aging” effects; mechanistically, it’s been studied for effects on telomerase and melatonin signaling. [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
The screenshot you shared lines up with how these peptides are often described in the media:
- BPC‑157 – proposed for ulcerative colitis and tissue healing
- KPV – wound healing and inflammatory conditions
- TB‑500 – wound healing
- MOTS‑c – obesity and osteoporosis
- Semax – certain neurologic disorders
- Epitalon – insomnia / sleep regulation [uchealth](https://www.uchealth.org/today/peptides-benefits-risks-and-fda-concerns/)
Again, these are investigational and used off‑label or in research contexts—not fully vetted, approved drugs.
***
## What changed recently with regulations?
In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to review seven peptides that had been in a regulatory gray zone. The question was not “Should these be FDA‑approved drugs?” but rather “Should compounding pharmacies be allowed to use these substances in customized compounded medications?”
The seven peptides reviewed were:
- BPC‑157
- TB‑500
- KPV
- MOTS‑c
- Semax
- Epitalon
- Emideltide (also called DSIP, delta sleep‑inducing peptide)
### The committee’s recommendations
After reviewing available data and safety concerns, the committee voted to recommend six of the seven peptides for inclusion on the FDA’s “503A Bulks List” (the list of bulk drug substances that can be used for traditional pharmacy compounding): [linkedin](https://www.linkedin.com/posts/agelessrx_longevity-peptides-fda-activity-7487948963954847745-Crhq)
Recommended for compounding (restrictions potentially loosened):
- BPC‑157
- KPV
- TB‑500
- MOTS‑c
- Semax
- Epitalon
Not recommended:
- Emideltide (DSIP) – this one was voted down.
This matters because for years, these peptides existed in a legal gray area, with the FDA generally advising against compounding them due to concerns about safety, purity, and lack of rigorous human data. The advisory committee’s new recommendation is a step toward allowing regulated compounding of six of these substances in the United States. [ajmc](https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding)
- These are advisory votes, not final law. The FDA still has to decide whether to accept the recommendations and then go through a rule‑making process before compounding pharmacies can legally produce them at scale. [linkedin](https://www.linkedin.com/posts/agelessrx_longevity-peptides-fda-activity-7487948963954847745-Crhq)
- None of these six peptides is an FDA‑approved medication. Recommendation for compounding is not the same thing as approval for a specific indication. [ajmc](https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding)
- Human data are limited, and most studies are small, short‑term, or preclinical. Long‑term safety and optimal dosing are not well established.
A federal advisory panel recently recommended that six of the most talked‑about peptides (BPC‑157, KPV, TB‑500, MOTS‑c, Semax, and Epitalon) be allowed for use in regulated compounding pharmacies, but they are not FDA‑approved, and the FDA still has to make a final decision.
***
## How I talk about peptides with patients
> When patients ask me about peptides, I start by reminding them that we already use peptide therapies every day—insulin and GLP‑1s being the most common. From there, I separate things into:
>
> - Standard‑of‑care peptide medications (like insulin and GLP‑1 agonists), where we have robust, large‑scale safety and efficacy data.
> - Investigational or compounded peptides, where early research is intriguing, but the evidence base is much thinner and long‑term safety is still being clarified.
Then I emphasize:
- We always anchor care in evidence‑based therapies first (nutrition, movement, sleep, mental health, and standard medications when appropriate).
- If we consider a compounded peptide, it’s done collaboratively, with informed consent, realistic expectations, and a clear exit plan if side effects or no meaningful benefit.
***
> Peptides are not magic bullets, and they’re not all created equal. Insulin and GLP‑1s are time‑tested, high‑impact peptide therapies that have transformed metabolic care. Newer peptides like BPC‑157, TB‑500, MOTS‑c, Semax, and Epitalon are intriguing and may soon be available through more regulated compounding pathways—but they still live in the “promising but unproven” category.
>
> If you’re curious about whether a peptide fits into your care plan, the most important step is a thorough conversation with a clinician who understands both the science and your health history, so any experimentation is deliberate, informed, and as safe as possible.
